The catecholamine dopamine (DA), activates two distinct classes of DA-specific receptors in the cardiovascular system and kidney-each capable of influencing systemic blood pressure. D 1 receptors on vascular smooth muscle cells mediate vasodilation, while on renal tubular cells they modulate sodium excretion. D 2 receptors on pre-synaptic nerve terminals influence noradrenaline release and, consequently, heart rate and vascular resistance. Activation of both, by low dose DA lowers blood pressure. While DA also binds to alphaand beta-adrenoceptors, selective agonists at both DA receptor classes have been studied in the treatment of hypertension. An unfavourable side-effect profile Keywords: dopamine; blood pressure; hypertension
Historical context
Dopamine (DA) was synthesised for the first time in 1910, simultaneously at the Wellcome Laboratories of Sir Henry Dale in Britain, and in Germany by Mannich and Jacobsohn. 1, 2 Initially, its pharmacological effects were thought to mimic those of the previously identified sympathomimetic amines, noradrenaline and adrenaline, raising blood pressure dose dependently. In 1942, Holtz reported a novel observation that administration of low dose dopamine to the guinea pig resulted in lowering of arterial pressure, but the significance of this finding remained unclear for another 20 years. 3 The depressor capacity of dopamine was confirmed in experiments in the anesthetised dog in 1959 by Goldberg and Sjoerdsma. 4 They demonstrated that low dose infusions of DA initially lowered diastolic pressure. As the infusion rate increased, cardiac output increased, while higher infusion rates led to increases in both systolic and diastolic pressures. 4 This capacity of DA to increase cardiac output without increasing peripheral resistance, a therapeutic 'Holy Grail' for the treatment of congestive heart failure, led to careful trials in man. It was during the first study in heart failure patients that Goldberg made the critical observation that DA promoted an impressive diuresis and natriuresis, which he correctly ascribed following further experiments, to direct effects on the kidney, independent of changes in cardiac output (for review see Goldberg 5 ). Having also shown that the pressor effects of high dose DA could be abolished by alpha-adrenoceptor blockade, Goldberg speculated that there were likely to be specific receptors for DA, which might modulate blood pressure reduction and might be exploited in the treatment of hypertension. Proof of the concept followed when he infused DA, following alpha-adrenoceptor blockade with phenoxybenzamine, in a severely hypertensive patient at Grady Hospital in Atlanta. Blood pressure fell dramatically during DA infusion. 6 The hypotensive effect was not seen during DA infusion alone. The search for selective dopamine receptor agonists commenced.
Dopamine receptors
Characterisation of specific DA receptors was approached from several angles over the past 30 years. Using classic physiology and pharmacology, Goldberg and Kohli 7 concluded that there were two distinct types of peripheral (that is outside the central nervous system (CNS)) receptors: DA 1 receptors on vascular smooth muscle, mediating vasodilation, and what they characterised as DA 2 receptors on pre-synaptic membranes of sympathetic nerve terminals, minimising noradrenaline release and also promoting vasodilation. 7 Using a biochemical approach, Kebabian and Calne 8 described D 1 receptors whose occupation activated adenylate cyclase and D 2 receptors either uncoupled from, or with opposite effects on, this second messenger. 8 More recent studies using molecular cloning techniques have identified at least seven structurally distinct DA receptors, but whose pharmacological effects are encompassed by the earlier two receptor model. In the modern hierarchical classification the two main groupings (D1 A with D1 B -known in the numerical system as D1 and D5, with the second group D2 A , D2 B and D2 C -numerical system D2, D3 D4 respectively) correspond functionally to Goldberg's DA 1 and DA 2 receptors. 9 All DA receptors belong to the G-protein linked superfamily, are located within the plasma membrane and possess seven transmembranous domains. The signal transduction pathways of DA receptors have not been fully characterised. D 1 receptors are linked to the Gs protein which activates adenylate cyclase with the resulting cAMP activating protein kinase A. D 2 receptors, in contrast, interact with Gi which inhibits adenylate cyclase, but may also activate certain potassium channels, inactivate calcium channels, or promote phosphoinosotide hydrolysis and arachadonic acid release. A D 1 receptor capable of activating phospholipase C, leading to the generation of inositol phosphates and diacylglycerol has been described in the kidney.
Peripheral DA 1 receptors have been found in a variety of vascular beds, in large numbers on renal and mesenteric arteries, and to a lesser degree in coronary, cerebral, cutaneous and skeletal arteries. They are also found in renal proximal and distal tubular cells, adrenal cortex and cardiac muscle cells. DA 2 receptors are found on pre-synaptic nerve terminals and in sympathetic ganglia. DA 1 receptors bind the prototypic agonist, fenoldopam and antagonist SCH 23390 while the corresponding ligands for DA 2 receptors include quinpirole and domperidone respectively.
Dopamine and the pathogenesis of hypertension
Several abnormalities in dopamine excretion or DA receptor signal transduction have been reported in hypertensive cohorts (for review, see Hussain and Lokhandwala. 10 Impaired urinary DA excretion has been reported in salt-sensitive hypertensive patients and in some low-renin hypertensives. Suppressed dopaminergic activity has also been described in offspring of hypertensive patients and in the prehypertensive phase in others. Infusion of DA in patients with essential hypertension has been reported to result in enhanced urinary cAMP excretion compared with normal controls. These data have been interpreted as suggesting distal renal tubular DA 1 receptor up-regulation in response to defective DA synthesis in hypertensive individuals. However, there are no experimental data available on receptor numbers or receptor ligand affinity in kidneys of hypertensive subjects.
Similar defects in DA excretion and responses to DA infusion have been reported in Dahl salt-sensitive rats. This strain also exhibits limited downregulation of Na,K-ATPase activity in response to dietary salt loading compared with salt-insensitive rats of the same strain. Activity of this enzyme in proximal tubular cells is normally regulated by DA 1 receptors. While urinary DA excretion is normal or increased in the spontaneously hypertensive rat (SHR), the natriuretic response to DA or fenoldopam infusion may be impaired. Finally, mutant mice deficient in D 1 receptors develop systolic and diastolic hypertension.
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Dopamine modulation in cardiovascular therapy
Following the elucidation of its pharmacology, several diverse methods have been used to exploit dopamine in treating heart failure, shock and hypertension. Infusion of DA became the gold standard treatment of acute heart failure and cardiogenic shock, and, in spite of a paucity of randomised clinical trial data, to preserve renal function during all forms of shock and acute renal impairment from diverse causes. However, the necessity for parenteral administration, and its simultaneous actions on several receptors, limited its therapeutic usefulness. Accordingly, much effort was expended on the development of specific receptor agonists and antagonists, inhibitors of dopamine-beta-hydroxylase to enhance endogenous concentrations, and pro-drugs designed to be administered orally for post-absorption conversion to DA. All of these approaches have been investigated in hypertension. Indeed, several of the compounds have been used as probes to determine whether abnormalities in DA genesis or actions might contribute to the pathogenesis of hypertension.
Pro-drugs and enzyme modulators
Clinical exploitation of DA focused initially on methods to enhance the availability of DA at its receptors either through the use of pro-drugs that might be administered orally or parenteral preparations with longer duration of action, largely for the treatment of congestive heart failure. Levodopa, ibopamine-the precursor of epinine which is active at DA 1 , beta-and alpha-adrenoceptors, and ␥-glutamyl-dopa (gludopa) another DA precursor, were studied clinically. All had some beneficial effects on cardiac output, but variable effects on vascular resistance, and all ultimately proved unreliable (for review see Murphy et al 12 ). An enzymatic approach to enhancement of tissue DA levels, with associated blockade of noradrenaline synthesis, is inhibition of dopamine ␤-hydroxylase (DBH). Fusaric acid, the first inhibitor, reduced blood pressure in SHR and in man. 13 It also caused an early tachycardia and enhanced noradrenaline release, probably due to a direct neuronal effect; it was eventually abandoned because of hepatotoxicity. Other agents (A32390 A, BRL8242 and bupicomide, a precursor of fusaric acid) also reduced BP, increased renal blood flow and sodium excretion, but were hampered by unsatisfactory side-effect profiles. The fact that recently described patients with total deficiency of DBH, suffer profound postural hypotension, has detracted further from this avenue of drug development.
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DA1 receptor agonists in hypertension
Mild to moderate hypertension A 30-year search for a selective DA1 receptor agonist proved fruitful eventually. Although several were synthesised, only the benzazepine derivative fenoldopam (SKF 82623) has been studied extensively. Its pharmacological characterisation was described originally by Hahn and colleagues in 1982; 14 it was finally approved for the treatment of severe hypertension in 1997. Early clinical trials used an oral formulation but its hypotensive effects were erratic and short-lived. These findings resulted from its poor oral bioavailability (less than 2%) and its short plasma half-life of about 10 min. 15 In the first study of parenteral fenoldopam in 17 mild hypertensives, Murphy et al 16 demonstrated a hypotensive effect that was linearly dose-related at infusion rates of 0.025-0.5 g/kg/min. Heart rate increased by 13 beats per minute while plasma catecholamine concentrations doubled. The tachycardia was later shown to be avoidable by prior betaadrenoceptor blockade.
In a second experiment, in 10 water-loaded mild to moderate hypertensives (average blood pressure 159/103 mm Hg), a 2-h infusion of fenoldopam decreased blood pressure to 144/90 mm Hg. Heart rate increased by 16 beats per min; there was no evidence of tachyphylaxis. In spite of blood pressure reduction, urinary flow increased by 50%, urinary sodium excretion trebled, but there was no increment in potassium excretion. Plasma renin activity increased by 50%. Renal blood flow, determined from clearance of para-amino-hippurate, rose by 42%, while glomerular filtration rate, measured by inulin clearance, increased by 6%. Similar results were seen in a further experiment in the same patient group, but without prior water loading. 16 There were few adverse reactions reported. Two of 17 patients described flushing. An unexpected finding was the observation that most patients exhibited flattening of T waves of the anterior and lateral leads on electrocardiography, with T-wave inversion occurring in four of 17 patients studied. While there had been earlier case reports of ECG changes following short-term administration of minoxidil, hydralazine or verapamil, the frequency of changes in fenoldopam-treated patients led Gretler et al 17 to study the phenomenon formally in a later randomised comparison of fenoldopam with nitroprusside. In 21 severely hypertensive patients, detailed analysis of digitised ECG recordings revealed that both fenoldopam and nitroprusside decreased T-wave amplitude in all leads, except AVR, while patients exhibited no other overt evidence of cardiac ischaemia. The authors concluded that ECG changes are common during acute blood pressure reduction and remain undetected unless sought systematically. They also speculated that acute changes in left ventricular geometry following acute blood pressure reduction might explain the observation since the height and duration of the T-wave depend on ventricular wall thickness and trans-mural conduction velocity.
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Fenoldopam in severe hypertension
Several large trials have been completed demonstrating substantial efficacy in severe hypertension. While hypotensive effects comparable to those seen with nitroprusside have been reported, fenoldopam has shown contrasting effects on renal function. In a randomised, controlled comparison of fenoldopam with nitroprusside in patients with accelerated hypertension and average blood pressure 219/137 mm Hg. Elliott 18 reported similar pressure reductions during titration with both agents. However, while there was little change in renal function following nitroprusside administration, urinary output, sodium excretion and creatinine clearance were enhanced by fenoldopam during the first 4 h of therapy. To what extent these effects of fenoldopam resulted from renovascular effects or from direct effects on renal tubular receptors could not be established. Interestingly, Aronson et al 19 have described contrasting effects of these two agents during a 60 mm Hg reduction in mean blood pressure in anaesthetised mongrel dogs; while the reduction in pressure by nitroprusside was accompanied by a 15% reduction in renal blood flow, fenoldopam increased blood flow by 15%.
In Elliott's study, the addition of frusemide and atenolol after 4 h allowed safe down-titration of fenoldopam. In some patients, fenoldopam was continued for up to 18 h without evidence of tachyphyllaxis. An unexpected observation was that fenoldopam caused a dose-dependent increase in intra-ocular pressure (IOP), from 16 prior to therapy to 20 mm Hg after 4 h, in spite of a sharp reduction in systemic BP. In contrast, patients randomised to nitroprusside experienced no change in IOP. Subsequent experiments revealed that fenoldopam enhances cyclic adenosine monophosphate (AMP) production in both canine and porcine ocular trabecular meshwork, an effect that can be blocked by prior treatment with the selective DA1 receptor antagonist SCH23390. 20 While this suggests that DA receptor modulation might have therapeutic applications in managing patients with glaucoma, the most practical implication is that fenoldopam might best be avoided in patients with prior history of raised IOP. The combination of a direct effect on aqueous humor kinetics with simultaneous reduction in ocular arterial perfusion pressure, as systemic blood pressure falls, might lead to retinal ischaemia.
In summary, fenoldopam meets most of the criteria for a preferred drug in hypertensive emergencies. It has a rapid, dose-dependent onset of action and a short plasma half-life, which permits efficient down-titration in the event of over-shooting the hypotensive target. It has additional beneficial effects on renal function acutely; whether these renal effects translate into better clinical outcome, such as avoidance of dialysis in patients with severe renal impairment, remains to be established.
